Clinical trials: Multiple Dose
Part A: Healthy Part B: Overweight or Obesity
A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and…
- Trial name
- NCT07160400
- Testing
- IBI3032 tablets
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Parkinson's Disease
Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
The objectives as stated in the study protocol were as follows: To investigate the safety and tolerability of three multiple dose regimens of BIA 3-202 (50 mg twice a day, 100 mg twice a day and 200 mg twice a day in healthy…
- Trial name
- NCT02763800
- Testing
- BIA 3-202
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Renal Impairment, Diabetes
Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients
This study assess the pharmacokinetics of vildagliptin in mild, moderate and severe renal impaired patients
- Trial name
- NCT00818571
- Testing
- Vildagliptin
- Where
- Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.
- Trial name
- NCT03105375
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Losec
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Healthy
Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers
Study to investigate pharmacokinetics, safety and tolerability of Buscopan® after single rising dose and after multiple rising doses
- Trial name
- NCT02261077
- Testing
- Hyoscine butylbromide
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers
To evaluate the safety, tolerability and pharmacokinetics of HEC53856 after single or multiple oral administration, as well as the food effect on the pharmacokinetics, in healthy non-elderly subjects.
- Trial name
- NCT03886688
- Testing
- HEC53856
- Where
- China
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy, Colitis, Ulcerative
A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2)…
- Trial name
- NCT04457960
- Testing
- JNJ-66525433
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Glabellar Frown Lines
A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
The primary objective is to demonstrate the safety and efficacy of DWP-450 (Botulinum purified neurotoxin, Type A) Injection in the treatment of moderate to severe glabellar lines associated with corrugator and/or procerus muscle…
- Trial name
- NCT02334423
- Testing
- Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Healthy Subjects
A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects
The study is a single center, double-blind, randomized, parallel group, multiple ascending dose study in 16 healthy male volunteers.
- Trial name
- NCT03648346
- Testing
- Cohort 1: HL217 Ophathalmic Solution BID, Cohort 2: HL217 Ophathalmic Solution QID
- Where
- France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
Healthy Volunteer
AZD7325 Multiple Ascending Dose Study
This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD7325 after single and repeated ascending doses.
- Trial name
- MAD (NCT00681915)
- Testing
- AZD7325
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants
A study to evaluate safety, tolerability and pharmacokinetics of QLS1128 sustained-release tablets and in combination with ritonavir tablets in healthy participants
- Trial name
- NCT05458076
- Testing
- QLS1128 A-Dose 1~5 and Ritonavir, QLS1128 C-Dose 1~3 and Ritonavir, QLS1128 D-Dose 1 and Ritonavir
- Where
- China
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy
Safety and PK of Nikkomycin Z in Healthy Subjects
The purpose of this study is to determine if nikkomycin Z is safe when administered at different dose levels for 14 days. The study will also determine blood levels and urinary excretion of nikkomycin Z in relation to dose…
- Trial name
- NCT00834184
- Testing
- nikkomycin Z
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Chronic Pain
Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects
A double-blind, placebo-controlled, phase I study to assess safety, tolerability and pharmacokinetics of single/multiple ascending doses of atb-346 orally administered in healthy male and female subjects.
- Trial name
- NCT03220633
- Testing
- ATB-346
- Where
- Canada
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Antibe Therapeutics Inc.
COVID 19
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent…
- Trial name
- NCT06698549
- Testing
- ALG-097558
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Healhty
Pharmacokinetics of Huperzine A Oral Solution in Healthy Participants
In this study, 4 dose groups are planned: Group 1 (0.22 mg, QD), Group 2 (0.22 mg, BID), Group 3 (0.44 mg, QD), and Group 4 (0.44 mg, BID).
- Trial name
- NCT07784335
- Testing
- Huperzine A Oral Solution
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD
Normal Healthy Subjects
Study to Evaluate HT-4253 in Healthy Subjects
The primary objectives of this study are to evaluate the safety and tolerability of HT-4253 when administered as single oral doses and multiple oral doses at escalating dose levels in healthy volunteer subjects.
- Trial name
- NCT06537817
- Testing
- HT-4253
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Halia Therapeutics, Inc.
Healthy Subjects
The PK/PD Study of SHR7280 Tablets in Healthy Subjects.
The primary objective of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR7280 tablets in healthy subjects.
- Trial name
- NCT04554043
- Testing
- SHR7280
- Where
- China
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy, Pharmacokinetics
Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety
The objectives of this study were (a) to evaluate the pharmacokinetics and to evaluate and compare the pharmacodynamics of ilaprazole and esomeprazole following a single dose (Day 1) and once daily (QD) administration for 5…
- Conditions
- Healthy, Pharmacokinetics, Pharmacodynamics, Ilaprazole
- Trial name
- NCT01820143
- Testing
- Ilaprazole, Esomeprazole
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.